While the efficacy of single‐receptor GLP‐1 RAs as exenatide has been demonstrated through two clinical studies on IIH patients [2, 8], our study presents the first large‐scale investigation of tirzepatide, a dual GIP/GLP‐1 receptor agonist [10], as an adjunctive therapy in IIH management. This evidence concerns the gene GCG and pseudotumor cerebri.